Assays for Tick-Borne Infections

Reagena has developed lateral flow immunochromatographic rapid tests and an enzyme immunoassay to be used as an aid in diagnosis of tick-borne infections.

The use of ReaScan® rapid tests enables reliable and rapid analysis of samples in primary care settings and outside central laboratories. Reagena EIA tests are suitable for manual and automated analysis of larger number of samples at the same time

ReaScan+ C6 LYME IgG

Product info

ReaScan+ LYME IgM/IgG Combo

Product info

Reagena C6 LYME IgM/IgG EIA

Product info

ReaScan TBE IgM

Product info

ReaScan CXCL13

Product info

ReaScan TBE IgM rapid test is intended for the qualitative detection of tick-borne encephalitis (TBE, FSME) virus specific IgM antibodies in human serum and cerebrospinal fluid (CSF).

For Lyme borreliosis diagnostics, Reagena has developed ReaScan+ C6 LYME IgG and ReaScan+ LYME IgM/IgG Combo rapid tests and Reagena C6 LYME IgM/IgG EIA enzyme immunoassay. These LYME tests are intended for both serum and CSF samples.

The chemokine CXCL13 is used as a supplementary biomarker to serology in diagnostics of inflammatory central nervous system (CNS) diseases. The concentration of chemokine CXCL13 has been found to be elevated especially in cerebrospinal fluid (CSF) of Lyme neuroborreliosis patients.

Reagena’s ReaScan CXCL13 – the first and only CXCL13 rapid test on the market – allows analysis of one CSF sample at a time.

Contact form

"*" indicates required fields

My data may be used for marketing, sales and customer communication.*
This field is for validation purposes and should be left unchanged.